CSO Dr Roly Foulkes discusses importance of immune resetting at Biotrinity 2019

Immune Regulation Limited (‘Immune Regulation’ or the ‘Company’) a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces that Dr. Roly Foulkes, Chief Scientific Officer, took part in a panel discussion titled “What’s New in Autoimmune Disease?” at the BioTrinity 2019 conference in London on 1 May 2019.

Alongside leading industry peers from Cambridge Immunology Network, Eli Lilly, M Ventures and UCL, Dr Foulkes discussed the importance of immune system resetting, potential targets for autoimmune drug development, priority autoimmune diseases for research and what biotechnology companies working in this space need to succeed.

Established in 2007, BioTrinity is Europe’s leading biopartnering and investment conference, It brings life science companies, academics, investors, and major pharmaceutical players together for partnering and to debate key industry themes and issues. Being selected to contribute to this panel is an endorsement of the potential of Immune Regulation’s approach.

Dr Foulkes commented, “Discussing the importance of immune resetting therapies in the treatment of autoimmune diseases with such a high calibre panel was an excellent opportunity to highlight our novel approach. Our technology has the potential to return an out-of-balance immune system to its normal state, putting patients into long-term disease remission, without the significant side effects seen with current chronic therapy.”

Enquiries
Immune Regulation
Richard Nagle, CEO
+44 (0)7809 525267
info@immuneregulation.com

Instinctif Partners
Melanie Toyne-Sewell / Rozi Morris
+44 (0)20 7457 2020

About Immune Regulation Limited
Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases. These therapies reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

Lead drug candidates, IRL201805 (‘1805) and IRL201104 (‘1104) have successfully completed Phase 1/2a and Phase 1 studies, respectively. Both molecules have demonstrated a durable regulation of the immune system for a significant time period after a single dose and both appear to have very clean safety profiles. They appear to modulate key cells of the immune system that control the inflammatory response, with a long duration of action following a single dose (‘1805, up to 12 weeks; ‘1104, up to 14 days) despite their short pharmacokinetic half-lives. Furthermore, despite regulating the immune system they do not appear to suppress host defence, having shown no impact to date on the body’s ability to fight infection. Rather, they are immunomodulators: they appear to reset the immune response with the potential for inducing long-term disease remission.

7 May 2019

Scroll to Top

Glen Giovanetti

Non-Executive Director

Glen Giovanetti has more than 35 years of experience in strategy and operational leadership in the life science industry as well as in financial governance, risk and reporting as EY’s Global Biotechnology Sector Leader and Life Sciences Sector Leader. He currently serves on the Board of Directors of Life Science Cares, Teon Therapeutics and XW Pharma.

Marla S. Persky

Non-Executive Director

Marla S. Persky currently serves as the chief executive officer and president of WOMN LLC. She has more than 25 years of international senior business and legal experience in the pharmaceutical industry having held numerous business and legal positions at Boehringer Ingelheim and Baxter International. She currently serves on the Boards of Directors of Xeris Pharmaceuticals, YGEIA Consulting Group, Primary Stages, World Neighbors and A Better Chance in Ridgefield.

Dora Rau

Senior Vice President, Quality

Dora Rau brings 25 years of experience in development and commercial operations for drugs, biologics, devices and combination products to the team. She has held numerous executive-level quality positions, with expertise in building quality systems and in leading teams to attain successful regulatory authority inspection outcomes and product approvals.

Jonathan Gold

Chief Financial Officer

Over the last 25 years, Jonathan Gold has been an institutional venture capitalist, a public fund manager, a founder, an operating executive, and a board member for companies across sectors including life sciences. In those roles, he was active in the development, financing and mergers and acquisitions for numerous public and private companies.

Team Members

Michael Albisser

Non-Executive Director​

Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

Dr. Isaac Cheng, m.d.

Non-Executive Director

Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in Boston USA, and Shanghai China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

Peter Greenleaf

Chairman

Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

Marylyn Rigby

VP of Marketing and Investor Relations

Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

Nancy Vinh

VP of Clinical Operations

Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

Team Members

Dr. Clare Burgess

Chief Development Officer

Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

Jeff Myers, m.d., ph.d

Chief Medical Officer

Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

Team Members
  • Nancy Vinh: Vice President of Clinical Operations

Dr. Roly Foulkes

Chief Scientific Officer

A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

Team Members

Jones w (woody) Bryan, ph.d.

Chief Business Officer

Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

Team Members

Perry Calias, ph.d.

Chief Operating Officer

Perry Calias, Ph.D., brings over 25 years of experience in pre-clinical and clinical development, CMC and global regulatory submissions across the drug and device sectors of healthcare. He has held numerous executive positions leading clinical and non-clinical operations, with a strong focus on diseases of the central nervous system and rare diseases.

Team Members

Jonathan Rigby, mba

Group Chief Executive Officer

As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.

Team Members
  • Carrie Vincent: Director, HR & Senior Executive Administration
  • Dr. Jones W. (Woody) Bryan: Chief Business Officer
  • Dr. Roly Foulkes: Chief Scientific Officer
  • Jonathan Gold: Chief Financial Officer
  • Jeff Myers, MD: Chief Medical Officer
  • Marylyn Rigby: VP Marketing & Investor Relations
  • Dr. Perry Calias: Chief Operating Officer